Shares of Moderna Inc. (MRNA) gained 1.2% in trading on Tuesday after the company announced that the European Medicines Agency authorized a third dose of its COVID-19 vaccine for people who are severely immunocompromised. The authorization applies to those who are least 12 years old who have waited at least 28 days since getting their second dose of the vaccine. The U.S. authorized a third of the Moderna and BioNTech (BNTX)/Pfizer Inc. (PFE) vaccines for the immunocompromised people back in August. Moderna's stock is up 216.1% so far this year, while the broader S&P 500 has gained 14.7%.
(END) Dow Jones Newswires
October 05, 2021 11:22 ET (15:22 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.